Beijing News (Reporter Zhang Zhaohui) On March 30, Hualan Bio released its 2021 annual performance report. During the reporting period, the company achieved operating income of about 4.436 billion yuan, a year-on-year decrease of 11.69%; the net profit attributable to shareholders of the listed company was about 12.99 100 million yuan, a year-on-year decrease of 19.48%. In addition, Hualan Biology plans to distribute cash dividends of 2.00 yuan (tax included) to all shareholders for every 10 shares, with a total of about 36.4873 million yuan in cash dividends.
Hualan Bio said that during the reporting period, the company strengthened epidemic prevention and control, restored plasma supply, and the blood product business remained stable. In 2021, the National Health Commission issued the “Instructions for Plasma Donors” (2021 edition), Each apheresis stationRelevant documents have been revised in accordance with the requirements of the new regulations, and the relevant requirements of the regulations have been implemented. Hualan Bio has further tapped the pulp mining potential of the existing pulp station. In 2021, Hualan Bio-pulp will be more than 1,000 tons, an increase from the same period of the previous year.
In addition, during the reporting period, Hualan Bio has done a good job in the production and sales of influenza vaccines, strengthened technological innovation and new product development, and steadily advanced the research and development of products under development. Among them, the quadrivalent influenza virus split vaccine (children’s dosage form) has completed all pre-market preparations, and obtained the drug listing approval in February 2022; the human rabies vaccine and the adsorbed tetanus vaccine successfully passed the on-site inspection of the State Drug Administration. The drug registration certificate is pending approval; the new coronary pneumonia vaccine (recombinant human type 5 adenovirus vector) has obtained the clinical trial approval, and the Phase II clinical work has been started, and other product development and clinical work are also progressing smoothly.
Hualan Bio is a national high-tech enterprise engaged in the research, development, production and sales of blood products, vaccines and genetically engineered products. It is one of the enterprises with high comprehensive utilization rate of plasma, more varieties and complete specifications in the industry.
Proofreading Lucy Return to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.